SEARCH:   Advanced

This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kim, S. H. Articles by Park, S. H. Search for Related Content PubMed PubMed Citation Articles by Kim, S. H. Articles by Park, S. H. Related Collections Neoplasia Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  Blood, Vol. 95 No. 1 (January 1), 2000: pp. 294-300 NEOPLASIA Viral latent membrane protein 1 (LMP-1)-induced CD99 down-regulation in B cells leads to the generation of cells with Hodgkin's and Reed-Sternberg phenotype Soon Ha Kim, Young Kee Shin, Im-soon Lee, Young Mee Bae, Hae Won Sohn, Young Ho Suh, Howe J. Ree, Martin Rowe, and Seong Hoe Park From the Department of Pathology, Institute of Allergy and Clinical Immunology, Seoul National University College of Medicine, Seoul, Korea; DiNonA Inc, Suwon, Korea; the Department of Diagnostic Pathology, Samsung Medical Center, Seoul, Korea; and the Department of Medicine, University of Wales College of Medicine, Cardiff, UK.     Abstract Top Abstract Introduction Materials and methods Results Discussion References Recently we reported that the down-regulation of CD99 (Mic2) is a primary requirement for the generation of Hodgkin's and Reed-Sternberg (H-RS) cells seen in Hodgkin's disease. In this study, we provide evidence that the down-regulation of CD99 is induced by high expression of Epstein-Barr virus (EBV) latent membrane protein 1 (LMP-1), which is highly expressed in H-RS cells of EBV-associated Hodgkin's disease. To investigate the effect of LMP-1 on the expression of CD99 in vitro, we established a stable cell line by transfecting an SV40-early promoter driven-LMP-1 expression construct into a neoplastic lymphoblastoid B cell line, IM9, in which the level of endogenous LMP-1 expression is almost negligible. In this cell line, the overexpression of LMP-1 led to the down-regulation of CD99 and the acquisition of morphological and functional characteristics of H-RS cells indistinguishable from those in lymph nodes of Hodgkin's disease patients and in CD99-deficient B cells. In addition, induced LMP-1 expression in an EBV-negative B cell clone, BJAB, directly caused the down-regulation of surface CD99 expression. Northern and Western analysis data, showing that overexpression of LMP-1 negatively influenced the expression of CD99, were supported by experiments in which a CD99 promoter-driven luciferase promoter reporter construct transfected into 293T cells was down-regulated when LMP-1 was coexpressed. Therefore, our data strongly suggest that the EBV LMP-1 protein plays a pivotal role in the down-regulation of CD99 via transcriptional regulation, which leads to the generation of the H-RS cells. (Blood. 2000;95:294-300) © 2000 by The American Society of Hematology.     Introduction Top Abstract Introduction Materials and methods Results Discussion References Hodgkin's disease is a malignant disorder morphologically characterized by low occurrence of mononuclear Hodgkin (H) and multinucleated Reed-Sternberg (RS) cells encompassed by abundant non-neoplastic infiltrates.1,2 Advances in the comprehension of H-RS cell origin have been made by several studies that include immunophenotyping, genotyping, and cytokine production of H-RS cells in Hodgkin's disease specimens or cell lines from Hodgkin's disease tissues.3,4 Indeed, uncontrolled production of various cytokines and high levels of transcription factors are common features of H-RS cells in Hodgkin's disease biopsy specimens and Hodgkin's disease-derived cell lines.5,6 While the use of biopsy material and isolated H-RS cells has the potential to answer many questions, the cellular origin of H-RS cells is still a matter of debate. Recently we reported that H-RS cells from lymph nodes of Hodgkin's disease patients are consistently devoid of CD99 expression at their surfaces and that loss of CD99 in neoplastic B cells leads to the generation of cells with H-RS phenotype.7 Epstein-Barr virus (EBV), a ubiquitous human herpesvirus, is implicated in several human malignancies such as endemic Burkitt's lymphoma, nasopharyngeal carcinoma, and posttransplantation lymphoproliferative disease. The virus is a potent transforming agent for normal human B cells, and infection of resting B cells in vitro regularly leads to the establishment of EBV-immortalized lymphoblastoid cell lines in which about 9 viral proteins are expressed. Several of these so-called latent viral proteins (including the nuclear antigens EBNA LP, EBNA1, EBNA2, EBNA3A, and EBNA3C and the latent membrane protein [LMP]-1) cooperate to effect EBV-mediated transformation of normal B lymphocytes.8 Of these latent genes, LMP-1 not only is essential for the in vitro transformation of B cells by EBV,9 but also has pleiotropic effects on cellular phenotype in vitro and in animal models,10-14 consistent with its playing an important role in the initiation or maintenance of EBV-induced tumors. With respect to Hodgkin's disease, it has been reported that EBV was detected in the lesions of about 50% of Hodgkin's disease cases studied,15,16 and that LMP-1 was highly expressed in H-RS cells in EBV-associated Hodgkin's disease.17-19 In addition, overexpression of LMP-1 favors the formation of multinucleated H-RS cells in L-428, a Hodgkin's disease-derived cell line.20 Because LMP-1 is highly expressed in H-RS cells from EBV-associated Hodgkin's disease patients and down-regulation of CD99 contributes to the production of H-RS-like cells, we investigated the possibility that LMP-1 might be involved in the regulation of CD99 expression. We show here that overexpression of LMP-1 leads to the down-regulation of CD99, which eventually causes the generation of H-RS-like cells.     Materials and methods Top Abstract Introduction Materials and methods Results Discussion References Tissues and cells Lymph nodes were obtained from patients with Hodgkin's disease. IM9 (immunoglobulin-secreting lymphoblast) and 293T (human embryonic kidney cell line) cells were obtained from American Type Culture Collection (ATCC, Rockville, MD). Stable-transfected Burkitt's lymphoma B-cell line (BJAB) clones with tetracycline-regulatable expression of LMP-1 were described previously.21 EBV-transformed cell lines were prepared in this laboratory as previously described.22 The cells were cultured in Dulbecco's modified Eagle's medium (DMEM) (IM9 and 293T) or RPMI 1640 (BJAB) (GIBCO BRL) supplemented with 10% fetal bovine serum (FBS), antibiotics, and 2 mM glutamine in a humidified incubator atmosphere of 5% CO2. BJAB-LMP-1 cells were maintained in 1 µg/mL tetracycline, and LMP-1 expression was induced by reculturing them in tetracycline-free medium for 2 days. Gene constructs and stable transfection LMP-1 expression constructs pSG5-LMP-1 and pcDNA3-LMP-1 were gifts of Dr. E. Kieff (Harvard University, Boston, MA) and Dr. C.V. Paya (Mayo Clinic, Rochester, NY), respectively. Some of the sequence of the 5' flanking region of human CD99 has been published previously,23 but additional upstream 5' flanking sequences were obtained in this study by the use of genomic library screening, subcloning, and DNA-sequencing methods described by Sambrook et al.24 An EMBL phage containing 6 kb was cloned by screening a human female peripheral blood leukocyte genomic library (Clontech Laboratories Inc, Palo Alto, CA), and an NcoI-EcoRI fragment containing 2430 nucleotides of the 5'-flanking region of CD99 was sequenced (unpublished data). The region from 1650 to +130 relative to the transcriptional initiation site was amplified by polymerase chain reaction by the use of primers 5'-CCCATGGTCACTCATATGTGGCTCAG-3' (sense strand) and 5'-GGGGTACCGAAGGCGGCAGGACAGATAC-3' (antisense strand) and subsequently ligated into Basic/pGL-2 (promoterless and enhancerless luciferase reporter vector, Promega) for transient expression assay in 293T cells. The construction of stable-transfected IM9 cells with pSG5 or pSG5-LMP-1 (Vec-TF or LMP-1-TF, respectively) was established as described elsewhere.7 Establishment and subcloning of stable cell lines were accomplished by culturing primary transfectants in the presence of 500 µg/mL of G-418 (GIBCO BRL) for 1 month. Establishment of tetracycline-regulated LMP-1-BJAB clones was accomplished by first transfecting BJAB cells with transactivator plasmid pJEF3, and selecting with 500 µg/mL Hygromycin-B (Boehringer), then transfecting with the LMP-1-responder plasmid, pJEF6, and selecting with 2 mg/mL G418.21 Immunofluorescence staining and flow cytometric analysis Samples of 106 cells were first incubated with relevant monoclonal antibodies (Abs) (10 µg/mL) in phosphate-buffered saline (PBS) containing 1% bovine serum albumin (BSA) and 0.1% sodium azide for 30 minutes at 4°C. These cells were then washed with PBS and stained with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse immunoglobulin (Ig)G antibody. Flow cytometric analysis was performed on a FACScan (Becton Dickinson, San Jose, CA). The antibodies were either obtained from hybridoma cultures or purchased: major histocompatibility complex (MHC) class I (W6/32, ATCC), CD15 (Becton Dickinson), and calnexin (Transduction Laboratories, Lexington, KY). The monoclonal antibody to CD99 (DN16) was developed in this laboratory.7 The secondary antibody used was an FITC-conjugated goat anti-mouse IgG Ab (Dako, Glostrup, Denmark). Confocal microscopic analysis For immunofluorescence labeling, 5 × 104 cells were cytospun onto poly-L-lysine-coated slides, permeabilized, and fixed in cold acetone/methanol (50%/50% vol/vol) for 10 minutes, and then blocked in PBS containing 10% FBS. The slides were stained and examined by confocal microscopy (BioRad 1024; Bio-Rad Laboratories, Hercules, CA). Cell cycle analysis An asynchronous population of IM9 transfectants in the log-phase of cell growth was examined for DNA content by flow cytometric analysis. The cells were fixed in 70% ethanol in PBS on ice, pelleted with RNase A (0.1 ng/mL) for 30 minutes at 37°C, and then stained with propidium iodide (40 µg/mL). The cell-cycle profiles (10,000 cells per sample) were analyzed on a FACScan (Becton Dickinson). Western blotting Cells were solubilized with 1% NP-40 in 50 mM Tris-HCl, pH7.4, 50 mM ethylenediaminetetraacetic acid, and 1 mM phenyl methyl sulfonyl fluoride. After the insoluble pellets were removed, the lysates were separated by 12.5% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis, electroblotted onto the nitrocellulose filters for probing with CS.1-4 (LMP-1), DN16 (anti-CD99), and anti-calnexin monoclonal antibodies. Specifically bound antibodies were detected with the use of peroxidase-conjugated goat anti-mouse IgG (Zymed, San Francisco, CA), and visualized with the enhanced chemiluminescence detection system (Amersham, Arlington Heights, IL). Northern blot analysis Total RNA was prepared from cells with TRIzol reagent (Life Technologies, Grand Island, NY), separated by electrophoresis on a 1.0% agarose/formaldehyde gel, and then transferred onto nylon membrane filters (Hybond-N+; Amersham International, Amersham, UK). The filters were hybridized at 42°C overnight with [-32P-dCTP]-labeled cDNA fragments, then washed under stringent conditions (65°C for 30 minutes in washing buffer composed of 0.2 × standard saline citrate and 0.1% SDS), and detected by autoradiography. A full-length CD99 cDNA was used as a probe. The filters were stripped and rehybridized with a cDNA probe for glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control. Transient transfection and luciferase assay To test the effect of LMP-1 expression on the CD99 promoter activity, 293T cells (1 × 106 cells per 60 mm plate) were transfected with 1 µg of the CD99 (1650/+130)-driven luciferase construct, 3 µg of an LMP-1 construct (pSG5LMP-1 or pcDNA3-LMP-1), and 1 µg of the internal control plasmid by the calcium phosphate precipitation method. After overnight incubation, cells were washed and cultured in complete culture media for 36 hours. Luciferase activity was measured for a 15-second time course with the use of a luminometer (Turner Designs, TD-20/20; Promega, Madison, WI) and luciferase assay system (Promega) with one-tenth of the total volume of cell extract. The human polypeptide binding protein (BiP)-based chloramphenicol acetyl transferase (CAT) reporter vector (containing the BiP promoter, kindly provided by Dr. Chao, Chang Gung Medical College, Taoyuan, Taiwan25) was used as an internal control for transfection efficiency. CAT assays were performed as previously described.26 Protein concentrations of cell extracts were measured with the use of the bicinchoninic acid protein assay reagent kit (Pierce, Rockford, IL). The luciferase activity of each sample was subsequently adjusted according to CAT activity and protein concentration per sample.     Results Top Abstract Introduction Materials and methods Results Discussion References Generation of H-RS-like cells by LMP-1 overexpression in IM-9, a lymphoblastoid B cell line The strong association of high expression of LMP-1 with multinuclear cell formation and our previous finding that down-regulation of CD99 induces the generation of H-RS-like cells prompted us to investigate the possible relationship between LMP-1 and CD99 molecules in H-RS cells. To investigate whether the overexpression of LMP-1 correlates with the modulation of surface expression of CD99 and produces cells with an H-RS phenotype, we first established a stable IM9 cell line transfected with SV40 immediate early promoter-driven LMP-1 gene (defined as LMP-1-TF). Interestingly, a significant number of LMP-1 TF cells showed the typical H-RS cell morphology, such as abundant cytoplasm and multilobed or multinucleated nuclei with amphophilic owl-eyed nucleoli compared with the vector-transfected IM9 cells (defined as Vec-TF) (Figure 1A, 1B). A high level of LMP-1 expression in LMP-1-TF IM9 cells compared with Vec-TF was confirmed by confocal microscopic analysis (Figure 1C, 1D) and immunoblot analysis (Figure 3B). This was also the case in the overexpression by LMP-1 of EBV-transformed B cells (data not shown). View larger version (70K): [in this window] [in a new window]   Fig 1. H-RS phenotype generated by LMP-1 overexpression in IM9 cells. (A, B) Both Vec-TF (A) and LMP-1-TF (B) IM9 cells were morphologically examined with Wright's and Giemsa staining. LMP-1 overexpressing IM9 cells showed typical H-RS morphology. (C, D) Vec-TF (C) IM9 cells and LMP-1-TF (D) IM9 cells were stained with anti-LMP-1 monoclonal antibody. LMP-1 expression was identified by incubation with FITC-conjugated goat anti-mouse antibody, and then was analyzed by confocal microscopy. Vec-TF cells showed minimal expression of LMP-1. (E, F) Vec-TF (E) IM9 cells and LMP-1-TF (F) IM9 cells were stained with FITC-conjugated anti-CD15 monoclonal antibody. While no CD15 expression was detectable in Vec-TF cells, the majority of enlarged LMP-1-TF cells showed relatively high expression of CD15 in Golgi and cytoplasmic regions. PI staining was included for nuclear staining in all samples except A and B. All slides were processed in parallel and photographed under identical magnification (original magnification ×630). Characterization of H-RS-like cells generated by LMP-1 overexpression It has been reported that a significant proportion of H-RS cells display the CD15+CD30+ phenotype, which is the immunophenotypic criterion for the diagnosis of Hodgkin's disease.27-31 Since H-RS-like cells were generated by LMP-1 overexpression in B cell lines in the present study, we investigated whether these H-RS-like cells share common immunological characteristics shown in H-RS cells from Hodgkin's disease and CD99-deficient H-RS-like cells previously reported.7 Enlarged LMP-1-TF IM9 cells expressed a low level of CD15 on their surface as confirmed by flow cytometric analysis (data not shown). However, confocal microscopic examination clearly demonstrated the unique pattern of CD15 localization in the majority of enlarged LMP-1-TF cells but not in Vec-TF cells (Figure 1E, 1F). Most of the H-RS-like cells showed intense expression of CD15 in Golgi/ER and cytoplasmic regions, whereas expression was either faint or almost completely absent on the plasma membrane (Figure 1E, 1F). These findings further support the idea that LMP-1 overexpression is accompanied by the immunophenotypic changes seen in H-RS cells. Neither LMP-1-TF nor Vec-TF cells showed any change in their expression levels of other surface molecules such as CD19, CD21, CD23, CD25, CD40, MHC class I/II, LFA-3, and CD80 (data not shown). The observation that MHC class I is expressed at similar levels in LMP-1-TF and Vec-TF cells is in agreement with several recent reports that H-RS cells in EBV-positive Hodgkin's disease express a considerable amount of MHC class I, whereas EBV-negative H-RS cells lack MHC class I expression.32,33 We next investigated the proliferation profiles of LMP-1-TF cells. LMP-1-TF IM9 cells showed slower kinetics of cell proliferation than did Vec-TF cells (Figure 2A), which was confirmed by 3H]-thymidine uptake assay (data not shown). Similar results were obtained in LMP-1-TF EBV-transformed B cells (data not shown). View larger version (17K): [in this window] [in a new window]   Fig 2. Characterization of LMP-1 overexpressing IM9 cells. (A) Slow growth rate of LMP-1 overexpressing cells. The same number (5 × 104/mL) of cells were plated in 10% FBS-DMEM media at day 0. The total cell numbers were counted at the indicated days. LMP-1 overexpressing cells show slower kinetics of cell proliferation than do vector-transfected cells. (B) Cell cycle analysis. Flow cytometric analysis was performed on asynchronously proliferating vector-transfected or LMP-1-transfected IM-9 cells. In order to elucidate the phase-distribution of cell cycle and possible arrest during a specific phase of cell cycle, the DNA contents of Vec-TF and LMP-1-TF IM9 cells were evaluated. LMP-1-TF cells revealed a substantial accumulation of 4N cells (5.21  24.7%) and contained a number of aneuploidy cells that were larger than 4N (0.23  7.11%) (Figure 2B). This finding indicates that the LMP-1-TF cells either are blocked at the mitotic (M) phase or are defective in cytokinesis. Overexpression of LMP-1 induces the down-regulation of CD99 This H-RS phenotype shown in the LMP-1-TF cells was accompanied by a substantial reduction of CD99 expression as revealed by flow cytometric analyses (Figure 3A). The down-regulation of CD99 molecules was also confirmed by immunoblot (Figure 3C) and Northern blot (Figure 3D), suggesting that CD99 down-regulation induced by LMP-1 overexpression is attributable mainly to a decrease in the synthesis of CD99 at the transcriptional level. These findings are consistent with the postulate that LMP-1 overexpression leads to the generation of cells with H-RS morphology through down-regulation of CD99. Since IM9 cells are originally infected with EBV, however, the possibility cannot be excluded that EBV proteins other than LMP-1 in LMP-1-TF cells reduce CD99 expression. View larger version (28K): [in this window] [in a new window]   Fig 3. Down-regulation of CD99 in LMP-1 overexpressing IM9 cells. IM9 B cells were transfected with either vector (Vec-TF), LMP-1 (LMP-1-TF), or antisense-CD99 (AS-TF) expression construct, and G418-resistant stable clones were obtained. (A) Flow cytometric analyses of LMP-1-TF cells. The cells were first stained with control monoclonal antibody or CD99 monoclonal antibody, and then with FITC-conjugated goat anti-mouse IgG antibody. (B) Vec-TF (V) and LMP-1-TF (L) IM9 cells were examined for LMP-1 expression by immunoblot. (C and D) Immunoblot and Northern blot analyses of LMP-1-TF IM9 cells. Expression of CD99 molecules was examined in Vec-TF (V), LMP-1-TF (L), and AS-TF (A) IM9 cells by immunoblot (C) and Northern blot (D) analysis. Calnexin (C) and GAPDH (D) were tested as internal controls. LMP-1-TF cells displayed down-regulation of CD99 expression at the transcriptional level. To confirm whether the overexpression of LMP-1 has a direct correlationship with the modulation of expression of CD99, we reinvestigated the relationship using stable-transfected EBV-negative BJAB cell clones with tetracycline-regulatable expression of LMP-1. Induction of LMP-1 expression in these LMP-1-BJAB cells following tetracycline removal was confirmed by immunohistochemical analysis (data not shown). The induced LMP-1 expression coincided with the appearance of H-RS-like cells (data not shown) and, in accordance with previous results,21 with the accumulation of cells at the G2/M phase of the cell cycle. Whereas induced expression of LMP-1 was observed in most of the cells in the absence of tetracycline, the multinucleated giant cells with H-RS morphology were more intensively stained for LMP-1. Consistent with CD99 down-regulation in LMP-1-TF IM9 cell clones, induction of LMP-1 in 1 LMP-1-BJAB clone (LMP-1 BJAB #3) resulted in a threefold to fourfold reduction in the levels of surface CD99, with no change of MHC class I expression (Figure 4). View larger version (14K): [in this window] [in a new window]   Fig 4. Effects of induced LMP-1 expression on CD99 molecules. tTA-BJAB and LMP-1-BJAB cells were grown in the presence (+) or absence () of tetracycline for 2 days before being harvested for indirect immnunofluorescence staining for CD99 (A) and MHC class I (B) with the use of the DN16 and W6/32 monoclonal antibodies, respectively. Stained cells were analyzed by flow cytometry, and the relative antigen intensity was calculated. LMP-1 down-regulates CD99 promoter activity when transiently co-transfected into 293T cells To confirm that LMP-1 modulates the CD99 expression at the transcriptional level, we performed transient transfection experiments with a CD99 promoter-driven luciferase reporter construct, pCD99(1650/+130)Luc, which contains 1780 nucleotides of CD99 5' flanking region including all putative Sp1 binding sites (see "Materials and Methods" and Figure 5A). The ubiquitously expressed transcription factor Sp1 binds GC-rich DNA elements and has been found to play a major role in the positive regulation of many TATA-less promoters.34,35 According to the sequencing data from others21 and our laboratory (unpublished data), the 5'-flanking region of CD99 contains no recognizable TATA element but a large number of binding sites for Sp1. In the present experiment, we utilized 293T cells, which express the endogenous CD99 gene with high promoter activity, to maximize the effect of co-transfected effector LMP-1 on pCD99(1650/+130)Luc. Upon co-transfection with SV40 early or CMV IE promoter-driven LMP-1, the CD99 promoter activity was markedly down-regulated. The effect of CMV IE promoter-driven LMP-1 was more dramatic than that of SV40 early promoter-driven, possibly owing to the higher expression of LMP-1. This finding strongly supports the previous Northern analysis data indicating the down-regulation of CD99 expression by LMP-1 at the transcriptional level. View larger version (12K): [in this window] [in a new window]   Fig 5. Transiently expressed LMP-1 down-regulates CD99 promoter-driven luciferase activity in 293T. (A) Schematic presentation of the CD99 promoter-driven luciferase construct pCD99(1650/+130)luc. Closed bars denote putative Sp1-binding sequences located at 287, 255, 164, 107, 61, 18, +11, and +61 relative to the transcription start site indicated as an arrow head. (B) Effect of LMP-1 expression on CD99 promoter activity. The mean values for 2 experiments are shown. The histogram shows the relative lucifersase activity normalized by the internal control plasmid, pBiP670CAT. In our experiment, we used a BiP promoter-driven CAT construct as an internal control plasmid to avoid using promoters that can be modulated by coexpressed LMP-1 or CD99, such as a -actin promoter. Transiently transfected LMP-1 or antisense-CD99 displayed little effect on the expression of BiP. This result was confirmed by comparison of the levels of BiP expression among the 3 stable-transfected IM-9 cell lines, Vec-TF, LMP-1-TF, and anti-CD99-TF in Western blot analysis (data not shown). Although it has been reported that the expression level of BiP is transiently modulated in cells in response to certain stresses,36,37 its expression is known to be fairly steady as a chaperone molecule under normal conditions. Down-expression of CD99 in H-RS cells from EBV-associated Hodgkin's disease patients We previously showed lack of CD99 expression in H-RS cells from Hodgkin's disease patients by immunohistochemical analysis.7 However, since these data were obtained in all but 3 cases with the use of paraffin-embedded tissues, we reexamined the level of CD99 expression by staining frozen Hodgkin's disease tissues. In 8 cases of EBV-negative Hodgkin's disease studied, H-RS cells were completely negative for CD99 expression by immunohistochemical and immunofluorescence analyses. In 5 cases examined, H-RS cells from EBV-positive Hodgkin's disease were all negative for the cell surface expression of CD99, except for 1 case with faint cytoplasmic expression in a few H-RS cells (Table 1).                                View this table: [in this window] [in a new window]   Table 1. CD99 expression in lymph nodes of EBV-positive HD patients     Discussion Top Abstract Introduction Materials and methods Results Discussion References We previously reported7 that down-expression of CD99 induces the generation of cells with the H-RS phenotype. Since more than 50% of Hodgkin's disease cases are known to be associated with the expression of EBV antigens and H-RS cells are frequently LMP-1-positive,15-19 we examined whether there was any correlation between the expression of CD99 and LMP-1 molecules. Upon stably transfecting an LMP-1 expressing construct into IM9 cells, the overexpressed LMP-1 led to the marked down-regulation of CD99 molecules, subsequently generating H-RS-like cells. Based on our observations, it is evident that LMP-1 causes a reduced expression of CD99 molecules mainly at the transcriptional level. Furthermore, the fact that the down-regulation of CD99 molecules was induced by regulated overexpression of LMP-1 in EBV-negative BJAB cells, argues against the possibility that CD99 down-regulation is an indirect spontaneous process of an as yet unidentified cellular adaptation to LMP-1 overexpression in EBV-positive IM9 cells. Although these results indicate that LMP-1 signaling events may suppress CD99 promoter activity via regulation of some molecules responsible for the transcription of CD99, the mechanism of the down-regulation of CD99 molecules by LMP-1 is not known at present. LMP-1 mediates its pleiotropic activities through at least 3 independent signaling pathways. LMP-1 triggers cellular NF-B activity through the TRAF signaling pathway,38-40 AP-1 activity through the SEK/JNK/c-JUN pathway,41,42 and the JAK/STAT pathway through binding and activation of JAK3.43 The involvement of these signaling pathways in the regulation of CD99 by LMP-1 is currently under investigation. LMP-1 overexpression in IM9 cells showed a negative effect on the rate of cell growth and an accumulation of cells at the G2/M phase, consistent with the previous report on the effect of LMP-1 expression in other cell lines.21 LMP-1-TF cells also exhibited H-RS morphology as shown in CD99-deficient B cells, suggesting that M-phase blockade by CD99 down-regulation is necessary for the production of H-RS cells in EBV-positive Hodgkin's disease. In support of this notion, it has been reported that multinuclear H-RS cells are derived from mononuclear Hodgkin's cells through disturbance of cytokinesis.20 Our data suggest that the formation of multinuclear cells by LMP-1 expression in L-428 and 293T is also attributed to LMP-1-mediated CD99 down-regulation.20 MHC class I down-regulation in H-RS cells was originally demonstrated by Poppema and Visser.32 However, several recent reports described high-level expression of MHC class I molecules on the H-RS cells of EBV-associated Hodgkin's disease, while expression of MHC class I molecules on EBV-negative H-RS cells was either extremely low or completely absent.33,44 In accordance with these reports, we confirmed that up-regulation of LMP-1 led to no change of MHC class I expression on the cell surfaces as compared with control cells, whereas CD99-deficient EBV-negative H-RS cells showed the down-regulation of MHC class I molecules.7 Our findings address a primary role of the down-regulation of CD99 by LMP-1 in the generation of the H-RS phenotype in EBV-associated Hodgkin's disease. In the pathogenesis of EBV-associated Hodgkin's disease, LMP-1 overexpression may be triggered by unknown factors induced in the microenvironmental milieu or genetic alterations in EBV-infected H-RS-precursor B cells, leading to the generation of H-RS cells by a subsequent decrease in the expression of CD99 at the transcriptional level. Previously, we demonstrated that the reduced expression of CD99 is a critical event in the development of Hodgkin's disease.7 In the case of EBV-associated Hodgkin's disease, the viral gene product LMP-1 is likely to play an important role in CD99 down-regulation. However, it is not clear by which mechanism CD99 expression is down-regulated in EBV-negative cases. Although some events, such as mutations in genes regulating CD99 expression or changes in cytokine milieu, are plausible, it remains to be determined what cellular factors are involved in CD99 down-regulation in the case of Hodgkin's disease not associated with EBV.     Acknowledgments We are grateful to Dr E. Kieff (Harvard University, Boston, MA), Dr C.V. Paya (Mayo Clinic, Rochester, NY), and Dr Chao (Chang Gung Medical College, Taoyuan, Taiwan) for providing us with LMP-1 gene and BiP promoter constructs, and to Sean Bong Lee (MGH Cancer Center, Boston, MA) for helpful comments on the manuscript.     Footnotes Submitted June 1, 1999; accepted August 18, 1999. S.H.K. and Y.K.S. contributed equally to this work. Supported by the `99 DiNonA Inc R&D Project, Seoul, Korea. MR was supported by the Leukemia Research Fund, London, UK. Reprints: Seong Hoe Park, Department of Pathology, Seoul National University College of Medicine, 28 Yongon-dong Chongno-gu, Seoul 110-799, Korea. The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.     References Top Abstract Introduction Materials and methods Results Discussion References 1. Drexler HG. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material. Leuk Lymphoma. 1992;8:283-313[Medline] [Order article via Infotrieve]. 2. Kadin ME. Pathology of Hodgkin's disease. Curr Opin Oncol. 1994;6:456-463[Medline] [Order article via Infotrieve]. 3. Gruss HJ, Pinto A, Duyster J, Poppema S, Herrmann F. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today. 1997;18:156-163[Medline] [Order article via Infotrieve]. 4. Haluska FG, Brufsky AM, Canellos GP. The cellular biology of the Reed-Sternberg cell. Blood. 1994;84:1005-1019[Free Full Text]. 5. Gruss HJ, Ulrich D, Braddy S, Armitage RJ, Dower SK. Recombinant CD30 ligand and CD40 ligand share common biological activities on Hodgkin and Reed-Sternberg cells. Eur J Immunol. 1995;25:2083-2089[Medline] [Order article via Infotrieve]. 6. Bargou RC, Leng C, Krappmann D, et al. High-level nuclear NF-kappa B and Oct-2 is a common feature of cultured Hodgkin/Reed-Sternberg cells. Blood. 1996;87:4340-4347[Abstract/Free Full Text]. 7. Kim SH, Choi EY, Shin YK, et al. Generation of cells with Hodgkin's and Reed-Sternberg phenotype through downregulation of CD99(Mic2). Blood. 1998;92:4287-4295[Abstract/Free Full Text]. 8. Kieff E. Epstein-Barr virus and its replication. In: Fields BN,Knipe DM,Howley PM, eds. Field of Virology. Vol 2. 3rd ed. Philadelphia, PA: Lippincott-Raven; 1996:2343-2396. 9. Kaye KM, Izumi KM, Kieff E. Epstein-Barr virus latent membrane protein 1 is essential for B-lymphocyte growth transformation. Proc Natl Acad Sci U S A. 1993;90:9150-9154[Abstract/Free Full Text]. 10. Dawson CW, Rickinson AB, Young LS. Epstein-Barr virus latent membrane protein inhibits human epithelial cell differentiation. Nature. 1990;344:777-780[Medline] [Order article via Infotrieve]. 11. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985;43:831-840[Medline] [Order article via Infotrieve]. 12. Wang D, Liebowitz D, Wang F, et al. Epstein-Barr virus latent infection membrane protein alters the human B-lymphocyte phenotype: deletion of the amino terminus abolishes activity. J Virol. 1988;62:4173-4184[Abstract/Free Full Text]. 13. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65:1107-1115[Medline] [Order article via Infotrieve]. 14. Wilson JB, Weinberg W, Johnson R, Yuspa S, Levine AJ. Expression of the BNLF-1 oncogene of Epstein-Barr virus in the skin of transgenic mice induces hyperplasia and aberrant expression of keratin 6. Cell. 1990;61:1315-1327[Medline] [Order article via Infotrieve]. 15. Herbst H, Niedobitek G, Kneba M, et al. High incidence of Epstein-Barr virus genomes in Hodgkin's disease. Am J Pathol. 1990;137:13-18[Abstract]. 16. Boiocchi M, De Re V, Dolcetti R, Carbone A, Scarpa A, Menestrina F. Association of Epstein-Barr virus genome with mixed cellularity and cellular phase nodular sclerosis Hodgkin's disease subtypes. Ann Oncol. 1992;3:307-310[Abstract/Free Full Text]. 17. Deacon EM, Pallesen G, Niedobitek G, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med. 1993;177:339-349[Abstract/Free Full Text]. 18. Herbst H, Dallenbach F, Hummel M, et al. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells. Proc Natl Acad Sci U S A. 1991;88:4766-4770[Abstract/Free Full Text]. 19. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lancet. 1991;337:320-322[Medline] [Order article via Infotrieve]. 20. Knecht H, McQuain C, Martin J, et al. Expression of the LMP1 oncoprotein in the EBV negative Hodgkin's disease cell line L-428 is associated with Reed-Sternberg cell morphology. Oncogene. 1996;13:947-953[Medline] [Order article via Infotrieve]. 21. Floettmann JE, Ward K, Rickinson AB, Rowe M. Cytostatic effect of Epstein-Barr virus latent membrane protein-1 analyzed using tetracycline-regulated expression in B cell lines. Virology. 1996;223:29-40[Medline] [Order article via Infotrieve]. 22. Walls EV, Crawford DH. Generation of human B lymphoblastoid cell lines using Epstein-Barr virus. In: Klaus GGB, ed. Lymphocytes: a Practical Approach. Oxford, England: IRL Press; 1987:149-162. 23. Goodfellow PJ, Mondello C, Darling SM, Pym B, Little P, Goodfellow PN. Absence of methylation of a CpG-rich region at the 5' end of the MIC2 gene on the active X, the inactive X, and the Y chromosome. Proc Natl Acad Sci U S A. 1988;85:5605-5609[Abstract/Free Full Text]. 24. Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory Press; 1989:2.82-2.121. 25. Chao CC, Yam WC, Chen LK, Lin-Chao S. Cloning of a functional Burkitt's lymphoma polypeptide-binding protein/78 kDa glucose-regulated protein (BiP/GRP78) gene promoter by the polymerase chain reaction, and its interaction with inducible cellular factors. Biochem J. 1992;286:555-559. 26. Gorman CM, Moffat LF, Howard BH. Recombinant genomes which express chloramphenicol acetyltransferase in mammalian cells. Mol Cell Biol. 1982;2:1044-1051[Abstract/Free Full Text]. 27. Kanzler H, Kuppers R, Hansmann ML, Rajewsky K. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med. 1996;184:1495-1505[Abstract/Free Full Text]. 28. Poppema S, De Jong B, Atmosoerodjo J, Idenburg V, Visser L, De Ley L. Morphologic, immunologic, enzymehistochemical and chromosomal analysis of a cell line derived from Hodgkin's disease: evidence for a B-cell origin of Sternberg-Reed cells. Cancer. 1985;55:683-690[Medline] [Order article via Infotrieve]. 29. Schmid C, Pan L, Diss T, Isaacson PG. Expression of B-cell antigens by Hodgkin's and Reed-Sternberg cells. Am J Pathol. 1991;139:701-707[Abstract]. 30. Hummel M, Ziemann K, Lammert H, Pileri S, Sabattini E, Stein H. Hodgkin's disease with monoclonal and polyclonal populations of Reed-Sternberg cells. N Engl J Med. 1995;333:901-906[Abstract/Free Full Text]. 31. Kuppers R, Rajewsky K, Zhao M, et al. Hodgkin disease: Hodgkin and Reed-Sternberg cells picked from histological sections show clonal immunoglobulin gene rearrangements and appear to be derived from B cells at various stages of development. Proc Natl Acad Sci U S A. 1994;91:10,962-10,966[Abstract/Free Full Text]. 32. Poppema S, Visser L. Absence of HLA class I expression by Reed-Sternberg cells. Am J Pathol. 1994;145:37-41[Abstract]. 33. Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic T-cell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood. 1996;87:3844-3851[Abstract/Free Full Text]. 34. Cornwell MM, Smith DE. SP1 activates the MDR1 promoter through one of two distinct G-rich regions that modulate promoter activity. J Biol Chem. 1993;268:19,505-19,511[Abstract/Free Full Text]. 35. Lu J, Lee W, Jiang C, Keller EB. Start site selection by Sp1 in the TATA-less human Ha-ras promoter. J Biol Chem. 1994;269:5391-5402[Abstract/Free Full Text]. 36. Munro S, Pelham HR. An Hsp70-like protein in the ER: identity with the 78kd glucose-regulated protein and immunoglobulin heavy chain binding protein. Cell. 1986;46:291-300[Medline] [Order article via Infotrieve]. 37. Li WW, Hsiung Y, Zhou Y, Roy B, Lee AS. Induction of the mammalian GRP78/BiP gene by Ca2+ depletion and formation of aberrant proteins: activation of the conserved stress-inducible grp core promoter element by the human nuclear factor YY1. Mol Cell Biol. 1997;17:54-60[Abstract]. 38. Miller WE, Mosialos G, Kieff E, Raab-Traub N. Epstein-Barr virus LMP1 induction of the epidermal growth factor receptor is mediated through a TRAF signaling pathway distinct from NF-kappaB activation. J Virol. 1997;71:586-594[Abstract]. 39. Brodeur SR, Cheng G, Baltimore D, Thorley-Lawson DA. Localization of the major NF-kappaB-activating site and the sole TRAF3 binding site of LMP-1 defines two distinct signaling motifs. J Biol Chem. 1997;272:19,777-19,784[Abstract/Free Full Text]. 40. Sandberg M, Hammerschmidt W, Sugden B. Characterization of LMP-1's association with TRAF1, TRAF2, and TRAF3. J Virol. 1997;71:4649-4659[Abstract]. 41. Kieser A, Kilger E, Gires O, Ueffing M, Kolch W, Hammerschmidt W. Epstein-Barr virus latent membrane protein-1 triggers AP-1 activity via the c-Jun N-terminal kinase cascade. EMBO J. 1997;16:6478-6485[Medline] [Order article via Infotrieve]. 42. Eliopoulos AG, Young LS. Activation of the cJun N-terminal kinase (JNK) pathway by the Epstein-Barr virus-encoded latent membrane protein 1(LMP1). Oncogene. 1998;16:1731-1742[Medline] [Order article via Infotrieve]. 43. Gires O, Kohlhuber F, Kilger E, et al. Latent membrane protein 1 of Epstein-Barr virus interacts with JAK3 and activates STAT proteins. EMBO J. 1999;18:3064-3073[Medline] [Order article via Infotrieve]. 44. Murray PG, Constandinou CM, Crocker J, Young LS, Ambinder RF. Analysis of major histocompatibility complex class I, TAP expression, and LMP2 epitope sequence in Epstein-Barr virus-positive Hodgkin's disease. Blood. 1998;92:2477-2483[Abstract/Free Full Text]. © 2000 by The American Society of Hematology.   CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: K.-C. Chang, Y. Chang, D. Jones, and I.-J. Su Aberrant Expression of Cyclin A Correlates With Morphogenesis of Reed-Sternberg Cells in Hodgkin Lymphoma Am J Clin Pathol, July 1, 2009; 132(1): 50 - 59. [Abstract] [Full Text] [PDF] A. Bremond, O. Meynet, K. Mahiddine, S. Coito, M. Tichet, K. Scotlandi, J.-P. Breittmayer, P. Gounon, P. A. Gleeson, A. Bernard, et al. Regulation of HLA class I surface expression requires CD99 and p230/golgin-245 interaction Blood, January 8, 2009; 113(2): 347 - 357. [Abstract] [Full Text] [PDF] J. H. Lee, S.-H. Kim, L.-H. Wang, Y.-L. Choi, Y. C. Kim, J. H. Kim, T. S. Park, Y.-C. Hong, and Y. K. Shin Clinical Significance of CD99 Down-Regulation in Gastric Adenocarcinoma Clin. Cancer Res., May 1, 2007; 13(9): 2584 - 2591. [Abstract] [Full Text] [PDF] H.-J. Byun, I.-K. Hong, E. Kim, Y.-J. Jin, D.-I. Jeoung, J.-H. Hahn, Y.-M. Kim, S. H. Park, and H. Lee A Splice Variant of CD99 Increases Motility and MMP-9 Expression of Human Breast Cancer Cells through the AKT-, ERK-, and JNK-dependent AP-1 Activation Signaling Pathways J. Biol. Chem., November 17, 2006; 281(46): 34833 - 34847. [Abstract] [Full Text] [PDF] M. C. Manara, G. Bernard, P.-L. Lollini, P. Nanni, M. Zuntini, L. Landuzzi, S. Benini, G. Lattanzi, M. Sciandra, M. Serra, et al. CD99 Acts as an Oncosuppressor in Osteosarcoma Mol. Biol. Cell, April 1, 2006; 17(4): 1910 - 1921. [Abstract] [Full Text] [PDF] Y.-L. Choi, Y. H. Xuan, Y. K. Shin, S. W. Chae, M. C. Kook, R. H. Sung, S. J. Youn, J. W. Choi, and S. H. Kim An Immunohistochemical Study of the Expression of Adhesion Molecules in Gallbladder Lesions J. Histochem. Cytochem., May 1, 2004; 52(5): 591 - 602. [Abstract] [Full Text] [PDF] A. Maitra, D. E. Hansel, P. Argani, R. Ashfaq, A. Rahman, A. Naji, S. Deng, J. Geradts, L. Hawthorne, M. G. House, et al. Global Expression Analysis of Well-Differentiated Pancreatic Endocrine Neoplasms Using Oligonucleotide Microarrays Clin. Cancer Res., December 1, 2003; 9(16): 5988 - 5995. [Abstract] [Full Text] [PDF] S. Gottschalk, O. L. Edwards, U. Sili, M. H. Huls, T. Goltsova, A. R. Davis, H. E. Heslop, and C. M. Rooney Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies Blood, March 1, 2003; 101(5): 1905 - 1912. [Abstract] [Full Text] [PDF] J. F. Garcia, F. I. Camacho, M. Morente, M. Fraga, C. Montalban, T. A. C. Bellas, A. Castano, A. Diez, T. Flores, C. Martin, et al. Hodgkin and Reed-Sternberg cells harbor alterations in the major tumor suppressor pathways and cell-cycle checkpoints: analyses using tissue microarrays Blood, January 15, 2003; 101(2): 681 - 689. [Abstract] [Full Text] [PDF] I.-s. Lee, M. K. Kim, E. Y. Choi, A. Mehl, K. C. Jung, M. C. Gil, M. Rowe, and S. H. Park CD99 expression is positively regulated by Sp1 and is negatively regulated by Epstein-Barr virus latent membrane protein 1 through nuclear factor-{kappa}B Blood, June 1, 2001; 97(11): 3596 - 3604. [Abstract] [Full Text] [PDF] K J Flavell and P G Murray Hodgkin's disease and the Epstein-Barr virus Mol. Pathol., October 1, 2000; 53(5): 262 - 269. [Abstract] [Full Text] P. Brennan, J. E. Floettmann, A. Mehl, M. Jones, and M. Rowe Mechanism of Action of a Novel Latent Membrane Protein-1 Dominant Negative J. Biol. Chem., January 5, 2001; 276(2): 1195 - 1203. [Abstract] [Full Text] [PDF] This Article Abstract Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kim, S. H. Articles by Park, S. H. Search for Related Content PubMed PubMed Citation Articles by Kim, S. H. Articles by Park, S. H. Related Collections Neoplasia Social Bookmarking                   What's this?

	Copyright © 2000 by American Society of Hematology         Online ISSN: 1528-0020